XFOR Stock Summary and Trading Ideas (X4 Pharmaceuticals | NASDAQ:XFOR)

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

X4 Pharmaceuticals trades on the NASDAQ stock market under the symbol XFOR.

As of November 6, 2026, XFOR stock price climbed to $3.18 with 509,107 million shares trading.

XFOR has a beta of 1.50, meaning it tends to be more sensitive to market movements. XFOR has a correlation of 0.09 to the broad based SPY ETF.

XFOR has a market cap of $324.72 million. This is considered a Small Cap stock.

Last quarter X4 Pharmaceuticals reported $3 million in Revenue and -$.16 earnings per share. This beat revenue expectation by $639,000 and exceeded earnings estimates by $.03.

In the last 3 years, XFOR traded as high as $48.00 and as low as $1.35.

The top ETF exchange traded funds that XFOR belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.

XFOR has underperformed the market in the last year with a return of -9.3%, while the SPY ETF gained +10.8%. In the last 3 month period, XFOR fell short of the market, returning -23.7%, while SPY returned -4.1%. However, in the most recent 2 weeks XFOR has outperformed the stock market by returning -1.9%, while SPY returned -3.2%.

XFOR support price is $2.90 and resistance is $3.24 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XFOR shares will trade within this expected range on the day.